NCT03503773已完成2 期
A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive Medications
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 350
- 试验地点
- 4
- 主要终点
- Changes in Systolic Ambulatory Blood Pressure
研究概览
简要总结
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
盲法说明
Blinded (The subject, sponsor, and hypertensionist/nephrologist performing the screening and follow-up assessments are blinded. The interventionalist and cath lab staff are unblinded.)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has 3 office blood pressure measurements with a mean office systolic blood pressure (SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of ≥90 mmHg.
- •Subject is willing to discontinue any current antihypertensive medications during the run-in period and the post-treatment period.
- •Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings
排除标准
- •Subject has renal artery anatomy abnormalities.
- •Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2, based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or is on chronic renal replacement therapy.
- •Subject has documented sleep apnea.
- •Subject has any of the following conditions: severe cardiac valve stenosis, heart failure (New York Heart Association [NYHA] Class III or IV), chronic atrial fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or right ventricular systolic pressure).
- •Subject is pregnant or lactating at the time of enrollment or planning to become pregnant during the trial time period (female subjects only).
- •Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal pulmonary inhalants are allowed.
- •Subject has a history of myocardial infarction, unstable angina pectoris, or stroke/TIA within 6 months prior to the planned procedure.
研究组 & 干预措施
Treatment Arm:
Experimental
Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
干预措施: Alcohol (Drug)
Sham Control Arm
Sham Comparator
Only renal angiography performed
干预措施: Sham control (Other)
结局指标
主要结局
Changes in Systolic Ambulatory Blood Pressure
时间窗: Baseline to 8 weeks post-treatment
Change from baseline in mean 24-hour ambulatory systolic blood pressure
次要结局
- Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months(6 months)
- Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months(12 months)
- Change in Office SBP at 8 Weeks(8 weeks)
- Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 8 Weeks(8 weeks)
- Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 6 Months(6 months)
- Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 12 Months(12 months)
- Number of Participants With Major Adverse Events (MAEs)(30 days post procedure)
- Use of Antihypertensive Medication(s)(8 weeks)
- Change in Mean Daytime Ambulatory Systolic Blood Pressure at 8 Weeks(8 weeks)
- Change in Mean Daytime Ambulatory Systolic Blood Pressure at 6 Months(6 months)
- Change in Mean Daytime Ambulatory Systolic Blood Pressure at 12 Months(12 months)
- Mean Daytime Ambulatory Diastolic Blood Pressure(8 weeks)
- Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 6 Months(6 months)
- Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 12 Months(12 months)
- Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 8 Weeks(8 weeks)
- Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 6 Months(6 months)
- Change in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months(12 months)
- Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 8 Weeks(8 weeks)
- Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 6 Months(6 months)
- Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 12 Months(12 months)
- Change in Mean Office SBP at 6 Months(6 months)
- Change in Mean Office SBP to 12 Months(12 months)
- Change in Mean Office DBP to 8 Weeks(8 weeks)
- Change in Mean Office DBP to 6 Months(6 months)
- Change in Mean Office DBP at 12 Months(12 months)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
不适用
DENEX Renal Denervation in Patients With Hypertension on no Antihypertensive MedicationsVascular DiseasesCardiovascular DiseasesHypertensionNCT04535050Kalos Medical100
撤回
不适用
Renal Denervation in Patients With Chronic Heart FailureCardio-Renal SyndromeChronic Heart FailureNCT02085668University Hospital, Saarland
已完成
不适用
Impact of Sympathetic Renal Denervation- a Study in Patients After Renal TransplantationRenal TransplantationSympathetic ActivityChronic Kidney DiseaseHypertensionNCT01899456Technical University of Munich18
Unknown
不适用
Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled HypertensionHypertensionNCT02029885Kona Medical Inc.132
终止
不适用
Single-arm Study of Symplicity™ Renal Denervation System in Patients With Uncontrolled HyperTensioN in IndiaAdults With Uncontrolled HypertensionNCT01632943Medtronic Vascular14